Heather Wheeler, DO
Family Medicine · Edmond, OKNPI 1124388293
Payments from drug & device makers
Across 211 payments — averaging $14.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$821
- Pfizer$694
- Astellas Pharma US Inc$207
- AstraZeneca$183
- Johnson & Johnson$162
- Novo Nordisk$143
- plus $887 from 20 others
What the payments were for
- Food & beverage$3,091100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 44 | $821 |
| Pfizer | 51 | $694 |
| Astellas Pharma US Inc | 14 | $207 |
| AstraZeneca | 12 | $183 |
| Johnson & Johnson | 24 | $162 |
| Novo Nordisk | 9 | $143 |
| Merck | 8 | $109 |
| GSK | 6 | $87 |
| Amgen | 6 | $87 |
| Amarin Pharma, Inc. | 6 | $82 |
| Shield Therapeutics Inc | 2 | $78 |
| Dexcom, Inc. | 5 | $77 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $46 |
| Organon | 3 | $44 |
| Lilly USA, LLC | 3 | $37 |
| Genentech USA, Inc. | 2 | $35 |
| Boehringer Ingelheim | 2 | $30 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Pharmacosmos Therapeutics Inc. | 1 | $25 |
| Sanofi-aventis U.S. LLC | 2 | $24 |
| Dynavax Technologies Corporation | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Nalpropion Pharmaceuticals LLC | 1 | $12 |
How this compares
$3,096 in reported general payments places this provider in the 80th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 47 | $66,128 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 45 | $65,883 |
| OzempicSemaglutide | 56 | $59,897 |
| JardianceEmpagliflozin | 42 | $57,820 |
| EliquisApixaban | 23 | $27,411 |
| TrulicityDulaglutide | 16 | $24,964 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 15 | $23,586 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $22,738 |
| JanuviaSitagliptin Phosphate | 35 | $21,863 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 15 | $7,119 |
| Xigduo XrDapaglifloz Propaned/Metformin | 11 | $6,299 |
| Atorvastatin Calcium | 363 | $5,407 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $4,060 |
| Dexlansoprazole DrDexlansoprazole | 14 | $3,633 |
| Omeprazole | 207 | $3,522 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskXultophy 100-3.6, Ozempic | $143 | $125,780101 claims |
| Lilly USA, LLCMounjaro, Trulicity | $37 | $91,09263 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $30 | $81,40657 claims |
| PfizerEliquis | $694 | $27,41123 claims |
| MerckJanuvia | $109 | $21,86335 claims |
| AstraZenecaSymbicort | $183 | $2,64712 claims |
| AbbVieSynthroid | $821 | $89216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Edmond
- Stanley ShadidEdmond$363K
- Susan DimickEdmond$256K
- Charles WoodwardEdmond$15K
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.